The Role of Adipokines In Atrial Fibrillation

• Conditions: Atrial Fibrillation; Adiposity; Hormone Disturbance; Adiponectin; Visceral Obesity
• Interventions: Other: Blood sample

• Registration Number: NCT03592732
• Lead Sponsor: University of Athens

Brief Summary

The principal aim of the present study is to analyze adiponectin, omentin-1, apelin and visfatin plasma levels in patients with and without AF in an effort to identify their potential role in the development of AF.

Detailed Description

Introduction Adipose tissue is no longer considered a triglycerides-storage depot, but it has been recognized as an endocrine organ that regulates sugar and fat metabolism and energy homeostasis and implicates in cardiovascular (CV) function through the release of bioactive factors, the so-called adipokines. Several adipokines including adiponectin, omentin-1, apelin and visfatin have been identified as well as their link with CV diseases and, particularly, coronary artery disease (CAD) (1-3).

However, the potential impact of adipokines in patients with atrial fibrillation (AF) has not still elucidated. Although, there is evidence that apelin (4,5) and omentin-1 (6) are inversely correlated with AF, available data in regard to adiponectin and visfatin are inconclusive (7-9).

Objectives The principal aim of the present study is to calculate adiponectin, omentin-1, apelin and visfatin plasma levels in patients with AF and controls matched for age and gender in an effort to identify their potential role in the development of AF.

Methods Study population. Overall, 40 patients with AF and 40 controls will be studied. Patients with CAD, heart failure, cardiomyopathy, cancer, significant valvular disease, rheumatic heart disease or stroke will be excluded. The present study is conducted in accordance with the Declaration of Helsinki and has been approved by the Ethics Committee of our Hospital. A written informed consent will be obtained from each participant.

A detailed profile including demographic characteristics (age, gender) and traditional CV risk factors (smoking, hypertension, dyslipidemia, diabetes mellitus) will be obtained from every patient. Body mass index was (BMI) will be calculated as bodyweight in kilograms divided by height in meters squared and will be estimated for all subjects. All participants will undergo either electrocardiogram or 24-hour Holter monitoring. AF patients will be divided into the following three groups: paroxysmal AF, persistent AF and permanent AF.

Definitions. Paroxysmal AF is defined as a history of one or more episodes of AF that were treated with pharmacological or electrical cardioversion within seven days. Persistent AF is defined a history of one or more episodes of AF over seven days that required pharmacological or electrical cardioversion) and permanent AF is defined as continuous AF for more than a year.

Echocardiography. Transthoracic echocardiography will be performed in every patient. Left atrial dimension, interventricular septal dimension, left ventricular (LV) end diastolic dimension and ejection fraction (EF) will be measured.

Laboratory analysis. Blood samples will be collected after 12-hour overnight fasting. Plasma adiponectin (RD195023100,Human Adiponectin, Elisa Bio Vendor Laboratory, Medicine Inc., Brno, Czech Republic), omentin-1, apelin (Phoenix Pharmaceuticals Inc, Burlingame, CA) and visfatin (Phoenix Pharmaceuticals, California, CA, USA) levels will be measured by the Elisa method. Natriuretic peptide, C-reactive protein (CRP) and parameters concerning lipid profile (total cholesterol, triglycerides, low-density cholesterol, high-density cholesterol), glycemic profile (plasma glucose, hemoglobin A1c) and renal function (urea, creatinine) will be measured by standardized enzymatic methods as well.

Statistical analysis. Continuous variables will be expressed as mean values ± standard deviation (SD). Comparisons of continuous variables will be performed by one-way analysis of variance (ANOVA). Categorical data will be expressed as absolute and relative frequencies. All data will be analyzed using Statistical Package for the Social Sciences (SPSS) version 18.0 and all tests will be 2-tailed with the 5% indicating level of significance.

Study Timeline

• Study Start: 2018-03-29
• Study First Submitted: 2018-06-28
• Study First Submitted QC: 2018-07-17
• Study First Posted: 2018-07-19
• Status Verified: 2021-01
• Primary Completion: 2021-01-29
• Study Completion: 2021-01-29
• Last Update Submitted: 2021-01-29
• Last Update Posted: 2021-02-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• healthy subjects without atrial fibrillation and subjects with paroxysmal, persistent or permanent atrial fibrillation

Exclusion Criteria

• Patients with coronary artery disease, acute coronary syndrome, heart failure (EF<50%), cardiomyopathy, cancer, significant valvular disease, rheumatic heart disease, chronic kidney disease (eGRF<30) or stroke will be excluded.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
A	Blood sample	Patients with atrial fibrillation
B	Blood sample	Patients without atrial fibrillation

Primary Outcome Measures

Name	Time	Method
adiponectin, omentin-1, apelin and visfatin plasma levels	blood sample collection analysis (day zero	adiponectin, omentin-1, apelin and visfatin plasma levels calculation by the Eliza method

Trial Locations

Locations (1)

LAIKO General Hospital, Athens, Greece; 🇬🇷 Athens, Greece